NO20084119L - Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter - Google Patents
Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenterInfo
- Publication number
- NO20084119L NO20084119L NO20084119A NO20084119A NO20084119L NO 20084119 L NO20084119 L NO 20084119L NO 20084119 A NO20084119 A NO 20084119A NO 20084119 A NO20084119 A NO 20084119A NO 20084119 L NO20084119 L NO 20084119L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical combination
- peptide
- inhibitor
- cancer treatment
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Foreliggende oppfinnelse angår en farmasøytisk kombinasjon som inneholder en Caseinkinase 2 (CK2) peptidinhibitor (navngitt P15) sammen med standard kjemoterapeutiske legemidler anvendt ved kreftbehandling og som administreres sammen, separat eller sekvensielt. De kjemoterapeutiske legemidlene inkluderer cisplatin, taxol, alkaloider fra Vinca, 5-fluoruracil, doxorubicin, cyklofosfamid, etoposid, mitomicin C, imatinib, iressa og velcade (vortezomib). Synergien mellom P15-peptidet og antikreftlegemidlene gir en effektiv konsentrasjon av hvert cytostatisk legemiddel i kombinasjonen som er fra 10 til 100 ganger lavere enn den for hvert cytostatisk legemiddel alene. Den farmasøytiske kombinasjonen beskrevet ifølge oppfinnelsen fremviser lav toksisitet sammenlignet med den som rapporteres fra antikreftterapeutiske midler og derfor representerer den en viktig fordel ved dens anvendelse ved kreftbehandling. Videre fører den sekvensielle administrasjonen av denne farmasøytiske kombinasjonen gjennom forhåndsbehandling med P15-peptidet til en kjemosensibilisering av refraktære tumorer ovenfor antikreftterapetutiske midler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20060049A CU23511B6 (es) | 2006-02-28 | 2006-02-28 | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
PCT/CU2007/000010 WO2007098719A1 (es) | 2006-02-28 | 2007-02-28 | Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20084119L true NO20084119L (no) | 2008-11-25 |
NO341904B1 NO341904B1 (no) | 2018-02-19 |
Family
ID=40134932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084119A NO341904B1 (no) | 2006-02-28 | 2008-09-29 | Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon |
Country Status (23)
Country | Link |
---|---|
US (3) | US8871725B2 (no) |
EP (1) | EP1997506B8 (no) |
JP (2) | JP5733880B2 (no) |
KR (1) | KR101454866B1 (no) |
CN (1) | CN101432012B (no) |
AR (1) | AR059645A1 (no) |
AU (1) | AU2007219572B2 (no) |
BR (1) | BRPI0708307B1 (no) |
CA (1) | CA2642943C (no) |
CL (1) | CL2015001086A1 (no) |
CU (1) | CU23511B6 (no) |
CY (1) | CY1114686T1 (no) |
DO (1) | DOP2007000040A (no) |
HK (1) | HK1132451A1 (no) |
MX (1) | MX2008011141A (no) |
MY (1) | MY150135A (no) |
NO (1) | NO341904B1 (no) |
PE (1) | PE20081191A1 (no) |
PL (1) | PL1997506T3 (no) |
RU (1) | RU2396974C2 (no) |
UY (1) | UY30175A1 (no) |
WO (1) | WO2007098719A1 (no) |
ZA (1) | ZA200807323B (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
CN109875998B (zh) * | 2019-01-24 | 2021-09-03 | 武汉大学 | 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物 |
CN110448699B (zh) * | 2019-06-12 | 2022-03-11 | 天津医科大学 | 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法 |
CU20200103A7 (es) * | 2020-12-18 | 2022-07-08 | Ct Ingenieria Genetica Biotecnologia | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
CN114712377B (zh) * | 2022-04-26 | 2023-08-15 | 江苏师范大学 | 断血流皂苷a在制造药物中的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
NZ535349A (en) * | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
US20060014987A1 (en) * | 2003-07-07 | 2006-01-19 | Lan Huang | Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
EP1694331B8 (en) * | 2003-12-09 | 2010-02-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods for suppressing an immune response or treating a proliferating disorder |
TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2006
- 2006-02-28 CU CU20060049A patent/CU23511B6/es active IP Right Grant
-
2007
- 2007-02-23 DO DO2007000040A patent/DOP2007000040A/es unknown
- 2007-02-27 AR ARP070100805A patent/AR059645A1/es not_active Application Discontinuation
- 2007-02-27 UY UY30175A patent/UY30175A1/es not_active Application Discontinuation
- 2007-02-28 AU AU2007219572A patent/AU2007219572B2/en active Active
- 2007-02-28 BR BRPI0708307-6A patent/BRPI0708307B1/pt active IP Right Grant
- 2007-02-28 RU RU2008138534/15A patent/RU2396974C2/ru active
- 2007-02-28 CN CN2007800152341A patent/CN101432012B/zh active Active
- 2007-02-28 MY MYPI20083318A patent/MY150135A/en unknown
- 2007-02-28 JP JP2008556646A patent/JP5733880B2/ja active Active
- 2007-02-28 PL PL07711104T patent/PL1997506T3/pl unknown
- 2007-02-28 CA CA2642943A patent/CA2642943C/en active Active
- 2007-02-28 WO PCT/CU2007/000010 patent/WO2007098719A1/es active Search and Examination
- 2007-02-28 MX MX2008011141A patent/MX2008011141A/es active IP Right Grant
- 2007-02-28 PE PE2007000215A patent/PE20081191A1/es not_active Application Discontinuation
- 2007-02-28 US US12/280,629 patent/US8871725B2/en active Active
- 2007-02-28 KR KR1020087023587A patent/KR101454866B1/ko active IP Right Grant
- 2007-02-28 EP EP07711104A patent/EP1997506B8/en active Active
-
2008
- 2008-08-23 ZA ZA200807323A patent/ZA200807323B/xx unknown
- 2008-09-29 NO NO20084119A patent/NO341904B1/no not_active IP Right Cessation
-
2009
- 2009-10-29 HK HK09110055.2A patent/HK1132451A1/xx not_active IP Right Cessation
-
2013
- 2013-02-15 CY CY20131100142T patent/CY1114686T1/el unknown
- 2013-07-12 JP JP2013146681A patent/JP2013231065A/ja not_active Withdrawn
-
2014
- 2014-09-19 US US14/490,856 patent/US9226946B2/en active Active
- 2014-10-20 US US14/518,242 patent/US9278118B2/en active Active
-
2015
- 2015-04-24 CL CL2015001086A patent/CL2015001086A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084119L (no) | Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter | |
ES2622559T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico | |
US20070280944A1 (en) | Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer | |
BRPI0721626A2 (pt) | combinaÇço farmacÊutica sinergÍstica para o tratamento de cÂncer | |
AU2017226389A2 (en) | Preparation and composition for treatment of malignant tumors | |
US8492397B2 (en) | Aminopyridine derivatives having Aurora A selective inhibitory action | |
KR20100126479A (ko) | 개선된 항종양 치료법들 | |
CA3167746A1 (en) | Compounds and uses thereof | |
ES2848706T3 (es) | Terapia de combinación contra el cáncer usando un compuesto azabicíclico | |
Min et al. | Autophagy as a potential target for sarcoma treatment | |
BR112019016668A2 (pt) | métodos para aumentar a concentração de plasma de durd e para inibir timidilato-sintase (ts) em um indivíduo humano. | |
US8481503B2 (en) | Combination cancer therapy with an AKT inhibitor and other anticancer agents | |
Huo et al. | Aqueous extract of Cordyceps sinensis potentiates the antitumor effect of DDP and attenuates therapy-associated toxicity in non-small cell lung cancer via IκBα/NFκB and AKT/MMP2/MMP9 pathways | |
Chen et al. | The antipancreatic cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2 | |
Tuttle et al. | Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells | |
CA3119395A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
Du Bois et al. | A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8) | |
Ge et al. | Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells | |
Badary et al. | Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL | |
KR20070019725A (ko) | 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도 | |
JP2007529540A5 (no) | ||
Salako et al. | Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines-a Case Study for Drug Reprofiling | |
JP5842367B2 (ja) | 抗癌剤増感剤 | |
Grossi et al. | Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations | |
He et al. | Application of median-effect in quantitative analysis of antitumor drugs in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |